Study Evaluating the Pronostic Value of Vascular Refilling Rate on Mortality in Chronic Kidney Disease Patients on Dialysis

Chronic Kidney Diseases Clinical Trial

— REMVAMIR  

Official title:

Evaluation of the Pronostic Value of Vascular Refilling Rate on Mortality in Chronic Kidney Disease Patients on Dialysis (Stage 5D)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04810338
• Other study ID #: RECHMPL20_0660
• Status: Completed
• Start date: January 1, 2018
• Est. completion date: September 1, 2021

Study information

• Verified date: April 2022
• Source: University Hospital, Montpellier
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Aim of this study is to evaluate in a population of chronic kidney disease patients on dialysis (Stage 5D) during an observational period of 3 years:

• the prognostic value of vascular refilling rate on mortality and on the occurrence of i) cardiovascular events and ii) hospitalization number

• the prognostic value of interdialytic weight gain on mortality and on the occurrence of i) cardiovascular events and ii) hospitalization number

• the prognostic value of perdialytic weight loss on mortality and on the occurrence of i) cardiovascular events and ii) hospitalization number.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 250
• Est. completion date: September 1, 2021
• Est. primary completion date: December 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Chronic Kidney Disease patient on dialysis (stage 5D) since at least september 2017 (3 months prior to study start date)

• Anuric patient

Exclusion criteria:

• Chronic Kidney Disease patient on dialysis with residual kidney function

Related Conditions & MeSH terms

• Chronic Kidney Diseases
• Kidney Diseases
• Renal Insufficiency, Chronic

Locations

Country	Name	City	State
France	Uhmontpellier	Montpellier

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prognostic value of vascular refilling rate on mortality	The refilling rate will be assessed by the ratio of relative blood volume	2 years after inclusion
Primary	Prognostic value of vascular refilling rate on mortality	The refilling rate will be assessed by the ratio of relative blood volume	3 years after inclusion
Primary	Prognostic value of vascular refilling rate on mortality	The refilling rate will be assessed by the ratio UF max	3 years after inclusion
Primary	Prognostic value of vascular refilling rate on mortality	The refilling rate will be assessed by the ratio UF max	2 years after inclusion
Secondary	Prognostic value of interdialytic weight gain	Prognostic value of interdialytic weight gain	2 years after inclusion
Secondary	Prognostic value of interdialytic weight gain	Prognostic value of interdialytic weight gain	3 years after inclusion
Secondary	Prognostic value of perdialytic weight loss	Prognostic value of perdialytic weight loss	2 years after inclusion
Secondary	Prognostic value of perdialytic weight loss	Prognostic value of perdialytic weight loss	3 years after inclusion